We are happy to announce that Juva Life has raised just over $17.5M USD from approximately 3,000 individual investors through its Regulation A+ offering that was qualified by the U.S. Securities and Exchange Commission (SEC) on August 21, 2019. Juva Life is one of the first cannabis companies to complete a Reg A+ filing with the SEC.

Under the offering, Juva will have issued approximately 35M units at a price of $0.50 USD per unit. Each unit is comprised of one common share of Juva stock and one half Juva share purchase warrant. Each warrant entitles the holder thereof to acquire one additional share of Juva stock at $0.75 USD per share for 18 months following the date of issuance.

The units issued in connection with the offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities laws.

Our Transfer Agent Odyssey Trust is preparing to send physical communication through traditional postal service at the time of this writing. The communication will include a DRS statement of ownership along with a valid Warrant Certificate.

Juva Life’s CEO, Doug Chloupek, said, “My dedicated team of scientists, researchers, operations specialists, and executive team are already in full swing. We are collectively motivated to know that such a large number of people believe as firmly as we do that cannabis is indeed an incredible gift and one whose medical applications deserve the attention of the scientific community. It’s time to ‘demystify’ cannabis’ many healing applications and share that with people.”

Juva Life is in the process of completing its 2019 audit and intends to file its non-offering prospectus with the British Columbia Securities and Exchange Commission (BCSC) in the coming weeks. Once Juva Life’s prospectus is cleared by the BCSC, the company will apply for both a listing on the Canadian Securities Exchange (CSE) and a dual listing on the OTC Markets in the US as a foreign issuer.

While Juva Life is vertically integrated, its strategy is cyclical and forward-moving. Juva Life’s founder, industry veteran Doug Chloupek, is aware of the limits facing California companies not fully vertically integrated — it forces them to be beholden to other companies for critical parts of their supply chain. By controlling cultivation, processing, distribution, and retail (through delivery and brick and mortar retail locations), Juva Life, when fully operational, will have limited its vulnerability and lowered middleman costs, effectively boosting margins.

Juva’s ultimate goal is to engage in the research and development necessary to create new and novel plant-based formulations that are the result of carefully designed scientific research. It hopes to provide a bridge to critical information previously hampered by cannabis’ Schedule 1 status.

Juva has various leased properties with a total of 10 local licenses (one State-approved) throughout one of the United States’ most progressive and affluent regions: the San Francisco Bay, Silicon Valley, and the Central Valley.

Redwood City delivery is fully licensed and operational and transacted its first sale in the second week of January. With a full staff and dedicated vehicles, marketing has begun and is building on the company’s already-existing strong community relationships. As the first operational, licensed delivery company in Redwood City, Juva Delivery has a six-month lead time advantage over the other five license holders. This location will deliver from San Bruno to Mountain View.

Stockton/San Juan is simultaneously in the first and second of three planned phases. Phase one includes the buildout of the front-of-house offices, as well as the distribution and delivery areas, all efficiently housed in one facility. Juva is targeting to have delivery and distribution operational in this facility by mid-2020. Phase two includes the build-out of the first three cultivation rooms; the goal is to begin planting in these rooms by July 2020, with the first harvests occurring in September 2020.

Hayward’s interior demolition is complete and Juva is currently awaiting approval on the installation of the facility sprinkler system, which, once completed, will allow Juva to begin utilization of its existing Class 5 cleanroom for important R&D work. Once fully constructed, Hayward will be ready for cultivation, manufacturing, retail, and distribution under Juva’s locally-approved microbusiness license. This location will also house a flagship retail store, currently under design, as well as provide space for patient consultations with qualified, medical staff.

Juva’s flagship facility in Hayward, CA.

Disclaimer

IMPORTANT: YOU MUST READ THE FOLLOWING INFORMATION 

The information contained in this communication (this “Communication”) has been prepared by Juva Life Inc. (“Juva” or the “Company”) and contains information pertaining to the business, operations and assets of the Company. The information contained in this communication (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate the Company and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company. The Company, it’s subsidiaries and affiliates, and any of its shareholders, directors, officers, agents, consultants, advisors or employees do not make any recommunication or warranty, express or implied, as to the accuracy, completeness or thoroughness of the information contained in this communication. The Company will not have any responsibility whatsoever in respect of the accuracy or completeness of, or omissions from, this communication or any other document or information, written or oral, supplied at any time to any recipient of this Communication or its subsidiaries, affiliates, agents or advisors in the course of its evaluation of the Company or in respect of any opinions, projections or other forward looking statements expressed therein or omitted therefrom. The Company expressly disclaims any liability resulting from the use of the information contained herein or otherwise supplied or resulting from the failure to supply additional information

THIS COMMUNICATION DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN JUVA.

Cautionary Note Regarding Forward Looking Information and Forward Looking Statements 

Certain statements in this Communication constitute forward-looking statements and forward-looking information within the meaning of applicable Canadian securities legislation (collectively herein referred to as “forward-looking statements”). All statements that address expectations or projections about the future, including statements about target returns, internal rates of return, project development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like “expects,” “believes,” “anticipates,” “plans,” “intends,” “projects,” “indicates,” and similar expressions. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other important factors, including, but not limited to, risk factors included in this Communication, that could cause the actual results, performance or achievements of Juva or industry results to differ materially from any future results, performance or achievements implied by such forward looking statements. Unanticipated events and circumstances are likely to occur and certain slides are based on closing conditions.

Factors that might cause these differences include but are not limited to: Unmet project completion deadlines affecting expected financial return; Unavailability of anticipated funds; Intense market competition resulting in lower than anticipated revenues; Higher than expected costs resulting in lower than anticipated revenues; General economic conditions such as the rate of unemployment, inflation, interest rates and the variability of the capital markets

These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward looking statements contained in this Communication, those results or developments may not be indicative of results or developments in subsequent periods. Although Juva has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward looking statements contained in this Communication are based on Juva’s current estimates, expectations and projections, which are based on the information available as of the date of this Communication. Prospective investors should not place undue reliance on any forward looking statement contained in this Communication. Forward looking statements contained in this Communication are made of the date of this Communication and, except as required by applicable law, Juva assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements contained in this Communication regarding past trends or activities should not be taken as a recommunication that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by Juva. In particular, historical results should not be taken as a recommunication that such trends will be replicated in the future. No statement in this Communication is intended to be nor may be construed as a profit forecast.

You may obtain a copy of our approved Reg A+ offering circular here.